ABOS Acumen Pharmaceuticals Inc.

FDA Catalyst Company
3.57
+0.34  (+11%)
Previous Close 3.23
Open 3.36
52 Week Low 3.02
52 Week High 26.98
Market Cap $144,572,548
Shares 40,496,512
Float 30,386,702
Enterprise Value $-59,383,616
Volume 78,861
Av. Daily Volume 244,597
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS EST. 1.82
EPS PRIOR. 1.82
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Credit Suisse Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 03/29/2022
B of A Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 01/21/2022
UBS Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/26/2021
B of A Securities Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/26/2021
Credit Suisse Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/26/2021
Stifel Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 07/26/2021

Latest News

    • Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer's disease
    • Frontiers in Neuroscience recently published a summary of preclinical evidence supporting the development of ACU193, a monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers (AβOs), for the potential treatment of early Alzheimer's disease
    • $216.7 million in cash, cash equivalents and marketable securities as of March 31, 2022, which is expected to provide cash runway through 2025
    • Company to host conference call and webcast today at 4:30 pm ET

    CHARLOTTESVILLE, Va. and CARMEL…

    View Full Article
  1. CHARLOTTESVILLE, Va. and CARMEL, Ind., May 11, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the company will report its financial results for the first quarter 2022 on Monday, May 16, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.

    Acumen will host a conference call and live audio webcast on Monday, May 16, at 4:30 pm ET. The live webcast may be accessed from the Investors section of the Company's website at www.acumenpharm.com. Please connect to the website prior to the start of the conference…

    View Full Article
  2. CHARLOTTESVILLE, Va. and CARMEL, Ind., April 27, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that Frontiers in Neuroscience published a summary of preclinical evidence supporting ACU193, a monoclonal antibody that selectively targets toxic soluble Aβ oligomers (AβOs) for the potential treatment of early Alzheimer's disease. The article is titled "ACU193: An immunotherapeutic poised to test the amyloid β oligomer hypothesis of Alzheimer's disease" and can be accessed here.

    Studies suggest that AβO-mediated neuronal toxicity is directly responsible for Alzheimer's-associated…

    View Full Article
    • Acumen is progressing ACU193, the first monoclonal antibody designed to selectively target toxic amyloid-beta oligomers (AβOs) to enter clinical testing
    • Currently enrolling INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer's disease
    • INTERCEPT-AD clinical trial design was presented at 2021 Clinical Trials on Alzheimer's Disease (CTAD) Conference in November 2021
    • Topline results from INTERCEPT-AD now expected in the first half of 2023
    • Acumen team expanded and Kim Drapkin appointed to the Board of Directors to enhance depth and breadth of expertise at the company
    • $225.9 million in cash, cash equivalents and marketable securities
    View Full Article
  3. CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease (AD), today announced that the company will report its financial results for the fourth quarter and full year 2021 on Monday, March 28, 2022. The company will host a conference call and live audio webcast at 4:30 p.m. ET to provide a business and financial update.

    Acumen will host a conference call and live audio webcast on Monday, March 28, at 4:30 pm ET. The live webcast may be accessed from the Investors section of the Company's website at www.acumenpharm.com. Please connect to the website prior to…

    View Full Article
View All Acumen Pharmaceuticals Inc. News